PMID- 10953979
OWN - NLM
STAT- MEDLINE
DCOM- 20010126
LR  - 20190116
IS  - 1042-8194 (Print)
IS  - 1026-8022 (Linking)
VI  - 38
IP  - 5-6
DP  - 2000 Aug
TI  - Generation of dendritic cells from human chronic myelomonocytic leukemia cells in 
      fetal calf serum-free medium.
PG  - 577-86
AB  - It is generally believed that the immune system plays a role not only in the 
      acquisition of malignant diseases but also in the rejection of microscopic as 
      well as established tumor cells. Failure of the immune system to eliminate tumor 
      cells may be, among other factors, due to an insufficient presentation of tumor 
      antigens. Dendritic cells (DCs), as professional antigen-presenting cells, 
      therefore, may be therapeutically used to initiate or enhance immune responses in 
      patients with malignancies. In this study we demonstrate that peripheral blood 
      cells of patients with chronic myelomonocytic leukemia (CMML) can be induced to 
      acquire DC characteristics. Upon culture with granulocyte-macrophage 
      colony-stimulating factor (GM-CSF) plus interleukin-4 (IL-4) plus tumor necrosis 
      factor alpha (TNFalpha), CMML cells develop DC morphology and acquire the 
      phenotypic characteristics of DCs. When a CD14+ cell population is used for DC 
      generation, a homogeneous differentiation towards the DC lineage occurs similar 
      to that, observed in normal peripheral blood monocytes. CMML-derived DCs are 
      potent stimulators of the allogeneic mixed lymphocyte reaction (MLR) when 
      compared with uncultivated cells. The demonstration of a deletion of the long arm 
      of chromosome 7, del(7)(q22), in 86% of highly enriched CD1a+ cells by 
      fluorescence in situ hybridization (FISH) indicates the leukemic origin of 
      generated DCs. In addition, we present data that generation of CMML-derived DCs 
      is also possible under fetal calf serum-free conditions for a potential clinical 
      use. These DCs may be used as a cellular vaccine to induce anti-tumor immunity in 
      patients with CMML.
FAU - Oehler, L
AU  - Oehler L
AD  - Department of Internal Medicine I, University of Vienna, Austria. 
      Leopold.oehler@univie.ac.at
FAU - Berer, A
AU  - Berer A
FAU - Keil, F
AU  - Keil F
FAU - Weinlander, G
AU  - Weinlander G
FAU - Konig, M
AU  - Konig M
FAU - Haas, O A
AU  - Haas OA
FAU - Lechner, K
AU  - Lechner K
FAU - Geissler, K
AU  - Geissler K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Culture Media, Serum-Free)
RN  - 207137-56-2 (Interleukin-4)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Cell Differentiation/immunology
MH  - Culture Media, Serum-Free
MH  - Dendritic Cells/immunology/*pathology
MH  - Granulocyte-Macrophage Colony-Stimulating Factor
MH  - Humans
MH  - Interleukin-4
MH  - Leukemia, Myelomonocytic, Chronic/immunology/*pathology
MH  - Tumor Cells, Cultured
EDAT- 2000/08/23 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/08/23 11:00
PHST- 2000/08/23 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/08/23 11:00 [entrez]
AID - 10.3109/10428190009059277 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2000 Aug;38(5-6):577-86. doi: 10.3109/10428190009059277.